<DOC>
	<DOC>NCT00918515</DOC>
	<brief_summary>This is a Phase I, single centre, open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of intravenous AZD3043 after single ascending doses in healthy male volunteers.</brief_summary>
	<brief_title>Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects aged 18 to 45 years with suitable veins for cannulation or repeated venepuncture Predose assessment judged without remarks by the investigator Have a Body Mass Index (BMI) between 19 and 30 kg/m2 and weight at least 50kg and no more than 100kg After adequate time (at least 15 minutes) of rest in supine position, abnormal vital signs defined as any of the following:· Systolic blood pressure (BP) &gt;140 mm Hg.· Diastolic BP &gt;90 mm Hg. Heart rate &lt;=55 or &gt;85 beats per minute Subjects with compromised airway or respiratory function as evidenced by the presence of Class 3 or 4 Airway, Sleep Apnoea, Neck circumference &gt; 16.5 inches (42 cm), Asthma, Active or recent (2 weeks) respiratory infection, or known chronic respiratory infection, or known chronic respirator Lack of a normal phenotype for butyrylcholinesterase (pseudocholinesterase)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Sedation</keyword>
	<keyword>Anaesthesia</keyword>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>healthy male volunteers</keyword>
</DOC>